These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 17921847)
1. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. Stastny MJ; Brown CE; Ruel C; Jensen MC J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847 [TBL] [Abstract][Full Text] [Related]
2. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287 [TBL] [Abstract][Full Text] [Related]
3. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828 [TBL] [Abstract][Full Text] [Related]
4. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190 [TBL] [Abstract][Full Text] [Related]
5. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study. Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW Front Immunol; 2021; 12():715000. PubMed ID: 34819930 [TBL] [Abstract][Full Text] [Related]
7. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138 [TBL] [Abstract][Full Text] [Related]
8. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Yang WQ; Senger D; Muzik H; Shi ZQ; Johnson D; Brasher PM; Rewcastle NB; Hamilton M; Rutka J; Wolff J; Wetmore C; Curran T; Lee PW; Forsyth PA Cancer Res; 2003 Jun; 63(12):3162-72. PubMed ID: 12810644 [TBL] [Abstract][Full Text] [Related]
9. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295 [TBL] [Abstract][Full Text] [Related]
10. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL. Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125 [TBL] [Abstract][Full Text] [Related]
11. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Dupont J; Latouche JB; Ma C; Sadelain M Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591 [TBL] [Abstract][Full Text] [Related]
12. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Ahmed N; Ratnayake M; Savoldo B; Perlaky L; Dotti G; Wels WS; Bhattacharjee MB; Gilbertson RJ; Shine HD; Weiss HL; Rooney CM; Heslop HE; Gottschalk S Cancer Res; 2007 Jun; 67(12):5957-64. PubMed ID: 17575166 [TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
14. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020 [TBL] [Abstract][Full Text] [Related]
15. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091 [TBL] [Abstract][Full Text] [Related]
16. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors. Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618 [TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741 [TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955 [TBL] [Abstract][Full Text] [Related]
19. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
20. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes. Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]